Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

NCT06422117 | Not Yet Recruiting Phase 3

• 1 other identifier: HSK16149-305
• Study Type: interventional
• Target: 408
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.

Conditions

Central Neuropathic Pain

Outcome Measures

Primary Outcomes (1)

• The changes of pain scores after treatment in HSK16149 group and placebo group were compared with baseline

  Changes in mean pain intensity (ADPS) at week 12 between HSK16149 and placebo were compared from baseline;The pain NRS score divides a straight line into 10 segments, with 0 to 10 indicating pain (a total of 11 points), 0 indicating no pain, and 10 indicating the most intense pain. The pain NRS scores of the past 7 days were collected and the average value was used as the ADPS score.

  week12

Study Arms (2)

HSK16149 20mg-40mg bid

EXPERIMENTAL

Oral administration of 20mg twice daily for 12 weeks can be adjusted to 40mg twice daily based on the efficacy and tolerability of the subject

Drug: HSK16149 20mg-40mg BID

Placebo

PLACEBO COMPARATOR

Placebo,Oral,2 capsules, twice daily for 12 weeks

Drug: Placebo

Interventions

HSK16149 20mg-40mg BID DRUG

Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;

HSK16149 20mg-40mg bid

Placebo DRUG

Placebo, oral, 2 capsules twice daily

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily sign an informed consent form;
• Able to read and complete survey questionnaires;
• Male or female patients aged ≥ 18 years old;
• The subject has a medical history and symptoms related to central neuropathic pain, including spinal cord related neuropathic pain (subject enrollment ≥ 50%), post-stroke central neuropathic pain, Parkinson's disease pain, and multiple sclerosis pain, and must meet the following criteria: a) pain duration ≥ 3 months; b) Characteristics that conform to neuropathic pain: DN4 scale score ≥ 4 points;
• During screening visits, patients were assessed to have an average pain visual analogue scale (VAS) score of ≥ 40 mm over the past 24 hours.

You may not qualify if:

• The presence of other painful diseases that may affect the evaluation of neuropathic pain;
• Patients with spinal cord injury or stroke whose condition is unstable and is expected to require surgical treatment;
• There is a chronic systemic disease that the investigator has assessed may affect the participant's participation in the study；
• Meet any of the following laboratory test results: a) Hematology: WBC\<3×109/L, N\< 1.5 ×109/L, PLT\< 75 ×109/L, or HB\< 90 g/L; b) Liver function: ALT or AST\> 2.5 × ULN; Or TBIL\> 1.5 × ULN; c) eGFR\< 60 mL/min/1.73 m2; d) Creatine kinase \> 2.0 × ULN;
• Women who are pregnant, planning to become pregnant during the study period, or breastfeeding; Women who do not wish to use reliable contraceptive methods (including condoms, spermicides, or Iuds) for 28 days after signing up for the ICF from the beginning to the last trial drug administration, or who plan to use progesterone contraceptives during this period;
• Mechanical operators engaged in high-altitude work, motor vehicle driving and other dangerous activities during the study period;
• Participated in any other clinical study within 30 days prior to screening;
• The investigator determined that there were other conditions that were not suitable for study participation.

Sponsors & Collaborators

• Haisco Pharmaceutical Group Co., Ltd.: lead

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2024
• First Posted: May 20, 2024
• Study Start: May 30, 2024
• Primary Completion (Estimated): July 30, 2027
• Study Completion (Estimated): August 7, 2027
• Last Updated: May 20, 2024

Record last verified: 2024-05